Acumen Pharmaceuticals Inc
NASDAQ:ABOS

Watchlist Manager
Acumen Pharmaceuticals Inc Logo
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Watchlist
Price: 1.95 USD 0.52% Market Closed
Market Cap: 118.1m USD

Acumen Pharmaceuticals Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acumen Pharmaceuticals Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Acumen Pharmaceuticals Inc
NASDAQ:ABOS
Operating Income
-$114m
CAGR 3-Years
-80%
CAGR 5-Years
-71%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Acumen Pharmaceuticals Inc
Glance View

Market Cap
118.1m USD
Industry
Biotechnology

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company is headquartered in Charlottesville, Virginia and currently employs 14 full-time employees. The company went IPO on 2021-07-01. The firm is engaged in developing a disease-modifying approach to target underlying cause of Alzheimer's disease (AD). The firm is focused on advancing a targeted immunotherapy drug candidate, ACU193, and establishing proof of mechanism in early AD patients. The firm's ACU193 is a humanized monoclonal antibody that selectively targets the anti-amyloid-beta oligomer (AbOs), has demonstrated functional and protective effects in in-vitro assays, and has demonstrated in-vivo safety and pharmacologic activity in multiple animal species including transgenic models for AD. The firm's therapeutic approach focuses on targeting AbOs, which is a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques.

ABOS Intrinsic Value
HIDDEN
Show

See Also

What is Acumen Pharmaceuticals Inc's Operating Income?
Operating Income
-114m USD

Based on the financial report for Dec 31, 2024, Acumen Pharmaceuticals Inc's Operating Income amounts to -114m USD.

What is Acumen Pharmaceuticals Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-71%

Over the last year, the Operating Income growth was -87%. The average annual Operating Income growth rates for Acumen Pharmaceuticals Inc have been -80% over the past three years , -71% over the past five years .

Back to Top